We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Evgen Pharma Plc | LSE:EVG | London | Ordinary Share | GB00BSVYN304 | ORD 0.25P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 0.80 | 0.75 | 0.85 | - | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 422k | -4.04M | -0.0147 | -0.54 | 2.2M |
Date | Subject | Author | Discuss |
---|---|---|---|
02/2/2021 17:34 | Evgen are all set for some serious upside as good news is delivered, fully funded for the foreseeable and multiple Transformational potential on multiple fronts...Grab 'em while you can, Evgen are on a one way Upward trajectory from now on in. Gla :-) | moneymunch | |
02/2/2021 17:25 | Better if they did none !! | nico115 | |
02/2/2021 17:22 | Rapid recruitment....DSMB' -- The Company is making good progress with recruitment for patients for its Phase II/III randomised, placebo-controlled STAR-COVID 19 trial, which is sponsored by the University of Dundee and funded by the UK charity Life Arc. As of 1(st) February 2021, this trial had recruited 89 patients. | moneymunch | |
02/2/2021 17:20 | Good it's out the way but i am surprised they didn't wait for the interim futility and safety analysis. Perhaps they are not confident the trial will continue. Also it's very disappointing that the directors aren't applying for shedloads of shares. Nevertheless no doubt I will apply for an excess of shares! And yes amaretto the record date is going to be next Wednesday. | nobbygnome | |
02/2/2021 17:17 | Well the sellers clearly got the heads up months ago, off loaded at 11p plus and are now picking them up at 8p all to the detriment of the ordinary share holder. No wonder they are over subscribed, clearly management were in bed with the market makers, poor form, but nothing that wasn't expected. | kingalf | |
02/2/2021 17:14 | More great news to come, The net proceeds of the Fundraising are intended to be used as follows: o to fund further preclinical work for metastatic breast cancer (mBC), glioma and a further cancer indication yet to be announced; | dutch123 | |
02/2/2021 17:12 | Incredible prospects and potential at hand and a shed load of cash...Gla :-) | moneymunch | |
02/2/2021 17:03 | Never been has happy on a placing day .. actually bought more ..Are the shares i bought today eligible for the 8 pence placing ones ?Oh and GDR tip closed at 94 pence !From 40 pence :-) | amaretto1 | |
02/2/2021 17:02 | Exciting times!!! Get ready for a mad dash for shares....On and Up!!! :-) | moneymunch | |
02/2/2021 16:47 | It was so obvious wasn't it down on 3 bits of huge news. Is the drug application in the US for SFX-01 something new?? Don't remember that before. Good news on the recruited patients as well at 89. | peanut100 | |
02/2/2021 16:38 | So there we have it. Those who were adamant there was not going to be a fund raising were completely wrong! At least the market seems to have seen it a positive light! | nobbygnome | |
02/2/2021 16:37 | open offer shares up 22.5% already! | jusjusjus | |
02/2/2021 16:31 | Maybe it was oversubscribed | awise355 | |
02/2/2021 16:27 | Well I never...On and Up!!! :-) | moneymunch | |
02/2/2021 16:26 | euclid, exactly my concern... BOD has such confidence that warrants an investment of a paltry £15K??? BS D | dennisbergkamp | |
02/2/2021 16:03 | It's the UK pharma scene, in the US their price would have bumped 50% on that glioma news and they would have raised $15m the next trading day. In the UK it's done the opposite way, which is bad for existing shareholders but great for new ones. Defies logic and needs to change, but it is what it is... | 74tom | |
02/2/2021 15:54 | Always pi$$es me of when a company boasts that a fundraising was 'heavily oversubscribed'. IMO that just means it was priced too low. | ewanwhose | |
02/2/2021 15:54 | Have been waiting for this news so bought in around 9p. A P2/3 Covid trial almost fully recruited and the market cap is just £25m with £10m cash?! GDR is sitting at £60m with a Covid test that it doesn't have any sales for yet... And I'd imagine they'll raise higher up if the trial is successful, like SNG did. There also seems to be a lot more besides Covid here to back up the market cap, the Glioma / Glioblastoma news was very exciting. There was a new ASX listing last week call Chimeric Theraputics that are focused on Glioblastoma, they have just started P1 and have a market cap of £50m. So undervalued here. | 74tom | |
02/2/2021 15:48 | "city boys" only get an 11% discount, more than happy with that in return for the company taking off. the raise will almost be in a few months time | jusjusjus | |
02/2/2021 15:47 | Poor small investment by the BoD's please don't tell me otherwise, £15,000 worth is that it???????????? Certain directors have agreed to subscribe for, in aggregate, 187,500 Placing Shares through the Placing, further information on which is set out below. | euclid5 | |
02/2/2021 15:45 | Exactly OT. It is what it is, but now we should be able to enjoy the ride. | bumpa33 | |
02/2/2021 15:45 | On target. The RNS says it may "potentially fund a clinical trial in glioma patients". It does not look to me that enough has been raised to fund a trial but welcome other views. | njb67 | |
02/2/2021 15:43 | Why raise now and not say in a few months time. Smacks of "city boys want their share of the pie before it takes off" as someone suggested the other day. | on target |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions